PD-L1 FDA (KEYTRUDA®) for NSCLC
Methodology
Immunohistochemistry (IHC)
Test Description and clinical significance
Disease:
NSCLC
In NSCLC, checkpoint inhibitors represent a new class of drugs that harness the body's immune system to attack tumor cells. They block the function of programmed death ligand 1 (PD-L1)/programmed death protein 1 (PD-1). PD-L1 protects normal cells from destruction during an infection by binding to PD-1 on activated T cells. Some tumor cells take advantage of the protective role of PD-L1 by expressing high levels of PD-L1 to evade the immune system. By blocking PD-L1/PD-1 function, checkpoint inhibitors enable the immune system to attack PD-L1–expressing tumor cells.
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed
for extended periods
Storage & Transport
Room Temperature
CPT(s)
88360
New York Approved
NO
TAT
2 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
